The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients with Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial

Keyphrases

• Placebo 100%
• Randomized Controlled Trial 100%
• COVID-19 100%
• Fluvoxamine 100%
• COVID-2 100%
• Clinical Deterioration 57%
• Oxygen Saturation 28%
• Intent-to-treat 28%
• High Risk 14%
• Hospitalization 14%
• United States 14%
• Placebo Groups 14%
• Randomized Double-blind 14%
• Placebo-controlled 14%
• Canada 14%
• Twice Daily 14%
• Clinical Trial Registry 14%
• Randomized Clinical Trial 14%
• Symptom Onset 14%
• Event Rate 14%
• Room Air 14%
• Shortness of Breath 14%
• Absolute Difference 14%
• Asymptomatic Infection 14%
• Multicenter Clinical Trial 14%
• Unvaccinated 14%
• Accruals 14%
• Data Safety Monitoring Board 14%
• Supplemental Oxygen 14%
• Background Prior 14%
• Non-hospitalized 14%
• Vaccine Availability 14%
• Lower Primary 14%

Medicine and Dentistry

• Placebo 100%
• Randomized Controlled Trial 100%
• Outpatient 100%
• COVID-19 100%
• Fluvoxamine 100%
• Deterioration 57%
• Clinical Trial 28%
• Intention-to-Treat Analysis 28%
• Oxygen Saturation 28%
• Primary Outcome 28%
• Infection 14%
• Dyspnea 14%
• Severe Acute Respiratory Syndrome Coronavirus 2 14%
• Randomized Clinical Trials 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Placebo 100%
• Randomized Controlled Trial 100%
• Fluvoxamine 100%
• Coronavirinae 100%
• Diseases 100%
• Deterioration 57%
• Clinical Trial 28%
• Infection 14%
• Randomized Clinical Trial 14%
• Dyspnea 14%
• SARS Coronavirus 14%